Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Our strategic aspiration is to move to more than is to more than double sales in obesity by 2025
Emerging Therapy Retatrutide Retatrutide is a new emerging (LY-3437943) is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under trial conducted by Eli Lilly and Company Mechanism of Action GIP agonism enhances insulin release, suppresses appetite, inhibits fat accumulation GLP-1 agonism enhances insulin release, suppresses glucagon, slows gastric emptying Glucagon receptor agonism boosts energy expenditure, supports glycemic control Collectively, it addresses glucose homeostasis, appetite regulation, energy metabolism, and weight loss Competitive Edge over Existing Therapies Superior efficacy: Around 24% weight loss surpasses GLP-1-only treatments (e.g., semaglutide, tirzepatide)
Daily, consistent supplementation for at least 8 to 12 weeks is recommended for meaningful results
Prescription GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are injectable drugs that have undergone extensive clinical trial processes and regulatory review
Not everyone with MTHFR variations develops histamine problems, and not everyone with histamine sensitivity has MTHFR issues
Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps
US$ 21.97
US$ 20.99
US$ 25.49
